Peter Millili

Johnson & Johnson
Senior Director, Manufacturing Science and Technology
Peter Millili received his Bachelors and Masters degrees in Chemical Engineering from Drexel University, and his Ph.D in Chemical Engineering from the University of Delaware. Previously, he worked at Merck & Co. in Vaccine Manufacturing, supporting technical elements associated with the purification, formulation, and lyophilization of live virus vaccines. Presently, he works at Bristol Myers Squibb, managing a group of scientists and engineers who support the development, technology transfer, and launch of new biologics in the Manufacturing Science and Technology organization. He has been an ISPE member for the past 15 years, and is currently an active member of the process capability sub-team of the PQLI technical team. He has presented at multiple conferences on the topic of formulation design, process development, and technology transfer of large molecules.
<!--March 2016, jbayne-->

Related Articles

Fast-Tracking-Drug-Development-750px.jpg
Technical
Fast-Tracking Drug Development: How Science, Strategy, and Structure Enabled Rapid CMC Success

This article presents experiences from seven recent accelerated development program case studies. These experiences provide insights that could help companies progressing through accelerated development programs for products meeting unmet medical needs or significant therapeutic needs, such as those with anticipated Breakthrough Therapy (United States) or PRIME (European Union) designation.

Post-approval Change Management for Cell and Gene Therapy Products
Features
Post-Approval Change Management for Cell and Gene Therapy Products

Cell and gene therapy (C&GT) products represent a significant step forward in patient treatment and often offer unique patient benefits. However, product developers face significant hurdles within the regulatory landscape. The tools laid out in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q12 guideline: “Technical and...